Subscribe To
Urinary catheters market value to expand at a 4.5% cagr from 2021 to 2028, reaching usd 5.1 billion: tmr report
A urinary catheter is a semi-flexible tube used to empty the bladder of urine. Urinart catheter usage i...
May 5, 2023, 6:30 pm
Immunitybio: fda approval potential in may of 2023
ImmunityBio, Inc. has a PDUFA date of May 23, 2023, for potential FDA approval of N-803 + BCG for the treatment of patients with BCG-unresponsive CIS ...
April 12, 2023, 4:08 pm
Aadi bioscience to present multiple posters at the american association for cancer research (aacr) annual meeting 2023
LOS ANGELES , April 6, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing a...
April 6, 2023, 4:35 pm
Vista outdoor stock falls more than 5% after company announces layoffs, cost cuts
Shares of Vista Outdoor Inc. VSTO, -0.69% dropped more than 5% in the extended session Monday after the outdoor and sporting goods maker said in a fil...
April 3, 2023, 4:25 pm
Urometer market to reach us$ 987.7 mn by 2032: tmr study
Increase in incidence of bladder dysfunction among the elderly population and surge in awareness about ...
January 5, 2023, 8:30 pm
Axonics to present at the 41st annual j.p. morgan healthcare conference
IRVINE, Calif.--( BUSINESS WIRE )--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel prod...
December 21, 2022, 6:00 am
Urogen pharma: jelmyto sales growing steadily, concerns remain
Shares have lost nearly two-thirds of their value over the past 3 years. RTGel platform is a great fit for bla...
November 21, 2022, 1:30 pm
Immunitybio: compelling data in bladder cancer, yet funding issues remain
Shares of ImmunityBio have lost nearly 90% of their value since merger with NantKwest last year. Ties to biotech billionaire Patrick Soon-Shiong are a...
August 7, 2022, 9:59 am
Seagen shares positive data for bladder cancer drug; stock is up 2.5%
Shares of Seagen Inc. SGEN, +0.71% gained 2.5% in premarket trading on Tuesday after the company said an early-stage clinical trial evaluating its inv...
July 26, 2022, 7:30 am
Sesen (sesn) halts bladder cancer drug development, stock down
Sesen Bio (SESN) decides to pause the development of Vicineum in the United States. It also ended its 2016 licensing agreement with Roche in exchange ...
July 19, 2022, 1:55 pm
Sesen bio pauses clinical development of its lead bladder cancer candidate in us
Based on a thorough reassessment Sesen Bio Inc (NASDAQ: SESN) has decided to voluntarily pause further development in the U.S. of its lead asset, ...
July 18, 2022, 8:35 am
4d pharma outlines phase ii plans for promising cancer drug candidate
4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) will deliver what's called a ‘trial in progress' poster at a world-leading cancer conference outlining the pla...
May 27, 2022, 2:50 am
Sonoma pharma launches new urinary tract infection product in new zealand, australia, south africa
Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) has launched Microdox, an urinary tract infection catheter and bl...
March 30, 2022, 11:27 am
Immunitybio: extensive pipeline, nda expected for anktiva this quarter
BLA filing of Anktiva + BCG in BCG-unresponsive cancer in Situ non-muscle invasive bladder cancer patie...
March 15, 2022, 5:39 pm
Kimberly-clark (kmb) boosts portfolio with thinx investment
Kimberly-Clark (KMB) acquires a majority stake in Thinx to create a portfolio of period and light bladder...
February 25, 2022, 10:45 am
Kimberly-clark (kmb) boosts portfolio with thinx investment
Kimberly-Clark (KMB) acquires a majority stake in Thinx to create a portfolio of period and light bladder...
February 25, 2022, 10:45 am
Kimberly-clark (kmb) boosts portfolio with thinx investment
Kimberly-Clark (KMB) acquires a majority stake in Thinx to create a portfolio of period and light bladder...
February 25, 2022, 10:45 am
Astellas pharma - seagen's enfortumab shows 36% pathologic complete response in bladder cancer patients
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) announced the initial results from Cohort H of the EV-103 trial investigating PADC...
February 15, 2022, 7:40 am
Astellas pharma - seagen's enfortumab shows 36% pathologic complete response in bladder cancer patients
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) announced the initial results from Cohort H of the EV-103 trial investigating PADC...
February 15, 2022, 7:40 am
Astellas pharma - seagen's enfortumab shows 36% pathologic complete response in bladder cancer patients
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) announced the initial results from Cohort H of the EV-103 trial investigating PADC...
February 15, 2022, 7:40 am